​

ZyVersa Therapeutics Stock (NASDAQ:ZVSA)

OwnershipFinancialsChart
ZyVersa Therapeutics by TradingView

Previous Close

-

52W Range

- - $0.30

50D Avg

$0.06

200D Avg

$0.15

Market Cap

$8.10K

Avg Vol (3M)

$8.74K

Beta

0.84

Div Yield

-

ZVSA Company Profile

ZyVersa Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to advancing and commercializing therapies for renal (kidney) and inflammatory disorders. The company's pipeline prominently features VAR 200, a cholesterol efflux modulator aimed at addressing kidney diseases such as focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease. Furthermore, ZyVersa is advancing IC 100, a pioneering inflammasome ASC inhibitor positioned to tackle a wide array of inflammatory conditions. The company maintains its corporate headquarters in Weston, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Feb 11, 2022

Website

ZVSA Performance

ZVSA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-25.49B$-9.14B$-14.42M
Net Income$-24.95B$-9.41B$-98.30M
EBITDA$-25.49B$-9.14B$-107.74M
Basic EPS$-4.18$-8.48$-1.09K
Diluted EPS$-4.18$-8.48$-1.09K

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
SLXNSilexion Therapeutics Ltd.
XAGELongevity Health Holdings Inc.
JSPRJasper Therapeutics, Inc.
ONCOOnconetix, Inc.
NIVFNewGenIvf Group Limited
CDTCDT Equity Inc.
INDPIndaptus Therapeutics, Inc.
ENVBEnveric Biosciences, Inc.